elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59
Q37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59
A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma
P2860
Q37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8da5557ad046c259f6b4d0b32aeba05305651adf
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.